Brain Tech Perceptions: New Study
- As neurotechnologies advance for treating brain-based conditions, understanding public perception is crucial.
- Participants rated each neurotechnology on perceived benefit, acceptability, risk, potential for changing one's personality, and likelihood of personal use.While familiarity with these technologies was generally low, openness to...
- The Neurotech Justice Accelerator at Mass General Brigham is working to understand public views about emerging neurotechnologies.
Public perceptions of neurotechnologies are under the microscope in a new study,and the results are telling. Researchers found that while many are open to neurotech interventions for brain conditions, the public views pills as the most beneficial and likely to be used. Deep brain stimulation, despite its potential, is seen as high-risk by many. The study, published in Device, assesses views on interventions for motor, mood, and memory symptoms, revealing how people weigh risks, change of personality, and benefits when considering thes advanced treatments. This is critical for the ethical rollout of neurotechnology. Perceptions also shifted based on what function was being targeted, which highlights the importance of tailoring these approaches for the best results, as detailed by the Neurotech Justice Accelerator. Learn more about these insights into public perspectives. As News Directory 3 keeps highlighting, understanding these viewpoints is crucial for the advance of brain tech. Discover what’s next as researchers examine how these perceptions shape the future.
Public Weighs Risks, Benefits of Neurotech for Brain Conditions
Updated May 26, 2025
As neurotechnologies advance for treating brain-based conditions, understanding public perception is crucial. Researchers surveyed over 1,000 U.S. adults about their views on four neurotechnologies: deep brain stimulation (DBS), MRI-guided focused ultrasound (MRgFUS), transcranial magnetic stimulation (TMS), and medication. the study, published in Device, explored perceptions of these interventions for severe mood, memory, or motor symptoms.
Participants rated each neurotechnology on perceived benefit, acceptability, risk, potential for changing one’s personality, and likelihood of personal use.While familiarity with these technologies was generally low, openness to considering them existed, especially for severe symptoms. Pills where the most favored option, with 61% open to considering them, followed by TMS (41%), MRgFUS (29%), and DBS (21%).
The Neurotech Justice Accelerator at Mass General Brigham is working to understand public views about emerging neurotechnologies. Unlike previous research that often focused on single technologies, this study directly compared four different approaches.
Deep brain stimulation (DBS) was considered the second most beneficial but also the riskiest and most invasive, making it the least likely to be used. This suggests that concerns about invasiveness and potential personality changes can outweigh perceived benefits. The type of symptom being treated also considerably influenced perceptions.
Participants viewed modulation for motor symptoms as significantly more acceptable and beneficial than those for mood symptoms, which were also seen as more invasive and more likely to change who someone is.
The study revealed that interventions for motor symptoms were seen as more acceptable and beneficial than those for mood symptoms, highlighting underlying beliefs about mental versus physical illness.Researchers emphasize that understanding these distinctions is vital for effective communication and ethical implementation of neurotechnologies.
What’s next
Future research will use network analyses to examine how perceptions of risk and benefit interrelate and influence openness to neurotechnology use. This will support the ethical development and communication of neurotechnologies that better reflect patient values and needs.